3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Breast Neoplasms
529
Neoplasms
475
Carcinoma, Non-Small-Cell Lung
394
Prostatic Neoplasms
308
Colorectal Neoplasms
296
Lung Neoplasms
259
Neoplasm Metastasis
218
Ovarian Neoplasms
200
Leukemia, Myeloid, Acute
199
Pancreatic Neoplasms
187
Multiple Myeloma
175
Squamous Cell Carcinoma of Head and Neck
134
Recurrence
132
Stomach Neoplasms
131
Brain Neoplasms
126
Carcinoma, Hepatocellular
125
Melanoma
124
Endometrial Neoplasms
122
Glioblastoma
118
Triple Negative Breast Neoplasms
111
Precursor Cell Lymphoblastic Leukemia-Lymphoma
106
Hematologic Neoplasms
100
Head and Neck Neoplasms
99
Lymphoma
97
Carcinoma, Renal Cell
97
Urinary Bladder Neoplasms
93
Sarcoma
90
Glioma
88
Lymphoma, Non-Hodgkin
82
Rectal Neoplasms
81
Interventions
atezolizumab
2
Etoposide
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Small Cell Lung Cancer Extensive Stage
×
90 days
×
Clear all
NCT05703971
2026-06-03
Acclaim-3
Genprex, Inc.
Phase 1/2
Recruiting
62 enrolled
NCT07227597
2026-05-28
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
170 enrolled